source
- STAT+: Argenx to buy Forte Biosciences for $2.2BArgenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune diseases.
- MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readoutWhile MapLight Therapeutics’ oral schizophrenia candidate reached the main endpoint of a Phase 2 trial, analysts say Bristol Myers Squibb's Cobenfy is likely to hold its market share.